NECLIFE · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 23/100 — Quality 33 · Momentum 0
| Share price | ₹12.07 |
| Market cap | ₹218 Cr |
| P/B ratio | 0.4 |
| ROCE | -8.7% |
| Book value | ₹28.98 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹0 Cr | ₹-293 Cr | -2,920.0% |
| 2025 | ₹1,664 Cr | ₹-114 Cr | -1.8% |
| 2024 | ₹1,682 Cr | ₹5 Cr | 9.0% |
| 2023 | ₹1,520 Cr | ₹-24 Cr | 3.5% |
| 2022 | ₹1,665 Cr | ₹25 Cr | 10.0% |
Nectar Lifesciences Limited manufactures, distributes, markets and sells pharmaceutical products in India and internationally. The company offers cephalosporins, includes pharmaceutical ingredients and intermediates comprising cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium, ceftriaxone sodium, cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil and sterile, cefprozil, cefdinir, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate, and cefepime +Arginine. It also provides contract manufacturing for finished dosage forms, such as tablets